Cambrex Inks Deal with Lilly to Support Biotech Collaborator Manufacturing
The Cambrex Longmont facility reportedly offers all services required to advance early-stage small molecules into the clinic.
Related Articles
After years of war, can Syria rebuild its ‘miserable’ scientific community?
Syrian researchers around the world begin to plan for the nation’s future
U.S. science funding agencies roll out policies on free access to journal articles
NIH and DOE are first to act, with implementation by all set to begin by end of 2025
When Infinity Yields Infinity: AI’s Mathematical Promise
Between every number lies an infinity, and now AI puts that boundless potential in our hands, transforming how we think and create.
Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trial
Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death…
Lights, Action, Bodycams in the ED
As violence in healthcare settings rise, can bodycams in the ED enhance safety for doctors and patients?
Lights, Action, Bodycams in the ED
As violence in healthcare settings rise, can bodycams in the ED enhance safety for doctors and patients?
Long-term in vitro expansion of a human fetal pancreas stem cell that generates all three pancreatic cell lineages
Identification of an LGR5 as a marker for a tripotent stem/progenitor cell of the human fetal pancreas. Organoids derived from single LGR5+ cells are capable…
Organoids Stand Out as Stand Ins in Drug Development
By capturing the genotypic and phenotypic heterogeneity of real tissues, organoids faithfully model human diseases and therapeutic responses.
AI writing is improving, but it still can’t match human creativity
Computer program finds that ChatGPT and its ilk remix words well, yet their output remains derivative